益丰药房
(603939)
| 流通市值：311.66亿 | | | 总市值：311.71亿 |
| 流通股本：12.12亿 | | | 总股本：12.12亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 11,721,819,634.46 | 6,009,043,521.27 | 24,062,154,701.73 | 17,218,897,862.76 |
| 营业收入 | 11,721,819,634.46 | 6,009,043,521.27 | 24,062,154,701.73 | 17,218,897,862.76 |
| 二、营业总成本 | 10,538,133,417.85 | 5,391,078,498.36 | 21,973,892,618.65 | 15,712,009,022.92 |
| 营业成本 | 6,978,503,709.93 | 3,627,192,865.13 | 14,408,310,539.42 | 10,263,836,853.11 |
| 税金及附加 | 45,086,433.38 | 22,824,215.56 | 95,485,533.5 | 69,011,236.33 |
| 销售费用 | 2,898,413,685.08 | 1,413,763,705.15 | 6,179,375,830.54 | 4,475,400,595.82 |
| 管理费用 | 521,175,430.3 | 279,180,393.48 | 1,082,881,741.13 | 756,145,104.2 |
| 研发费用 | 14,989,054.06 | 6,821,657.73 | 33,935,812.25 | 25,185,648.1 |
| 财务费用 | 79,965,105.1 | 41,295,661.31 | 173,903,161.81 | 122,429,585.36 |
| 其中:利息费用 | 101,032,831.38 | 54,675,521.2 | 221,373,934.51 | 159,590,829.88 |
| 其中:利息收入 | 33,131,338.63 | 19,865,240.25 | 72,647,179.88 | 55,481,384.79 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 69,308,547.03 | 27,186,162.03 | 108,128,784.49 | 76,803,405.41 |
| 资产处置收益 | 33,874,543.07 | 16,762,834.75 | 49,938,810.67 | 22,817,878.75 |
| 资产减值损失(新) | -46,492,233.84 | -22,763,668.03 | -102,396,476.85 | -59,754,324.5 |
| 信用减值损失(新) | 2,345,501.51 | -2,583,788.33 | 2,154,986.62 | -2,153,705.2 |
| 其他收益 | 29,625,844.26 | 13,975,298.59 | 57,736,157.07 | 40,942,345.23 |
| 四、营业利润 | 1,272,348,418.64 | 650,541,861.92 | 2,203,824,345.08 | 1,585,544,439.53 |
| 加:营业外收入 | 4,061,717.88 | 1,576,318.95 | 12,735,226.42 | 8,127,203.89 |
| 减:营业外支出 | 12,820,341.58 | 4,289,327.1 | 34,112,189.78 | 13,679,482.67 |
| 五、利润总额 | 1,263,589,794.94 | 647,828,853.77 | 2,182,447,381.72 | 1,579,992,160.75 |
| 减:所得税费用 | 317,795,858.56 | 154,279,572.7 | 529,665,095.86 | 381,573,694.73 |
| 六、净利润 | 945,793,936.37 | 493,549,281.07 | 1,652,782,285.86 | 1,198,418,466.02 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 945,793,936.37 | 493,549,281.07 | 1,652,782,285.86 | 1,198,418,466.02 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 880,045,883.2 | 449,493,528.8 | 1,528,576,669.36 | 1,110,500,691.55 |
| 少数股东损益 | 65,748,053.18 | 44,055,752.27 | 124,205,616.5 | 87,917,774.47 |
| 扣除非经常损益后的净利润 | 857,117,299.17 | 437,985,342.56 | 1,497,081,296.82 | 1,091,854,107.93 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.73 | 0.37 | 1.26 | 0.92 |
| (二)稀释每股收益 | 0.71 | 0.36 | 1.24 | 0.92 |
| 八、其他综合收益 | 32,352,825 | 9,609,750 | -69,190,200 | -89,370,675 |
| 归属于母公司股东的其他综合收益 | 32,352,825 | 9,609,750 | -69,190,200 | -89,370,675 |
| 九、综合收益总额 | 978,146,761.37 | 503,159,031.07 | 1,583,592,085.86 | 1,109,047,791.02 |
| 归属于母公司股东的综合收益总额 | 912,398,708.2 | 459,103,278.8 | 1,459,386,469.36 | 1,021,130,016.55 |
| 归属于少数股东的综合收益总额 | 65,748,053.18 | 44,055,752.27 | 124,205,616.5 | 87,917,774.47 |
| 公告日期 | 2025-08-29 | 2025-04-29 | 2025-04-29 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |